Your session is about to expire
← Back to Search
Senolytic + Anti-Fibrotic Agents for Osteoarthritis
Study Summary
This trial is testing whether a senolytic agent (Fisetin) and an anti-fibrotic agent (Losartan), used independently or in combination, can improve the beneficial effect of an active control (injection of autologous bone marrow aspirate concentrate (BMAC) into an osteoarthritic knee).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 55 Patients • NCT04771611Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the requirements for participants in this research?
"The study requires 100 individuals with osteoarthritis in their knees, aged between 40-85. These candidates must report a pain score of 3-10 on the target knee and a difference of at least 2 points compared to the contralateral knee within the past week."
How many people are taking part in this experiment at most?
"That is correct. The information available on clinicaltrials.gov supports that this study is presently recruiting patients. This trial was first advertised on May 18th, 2021 and has been updated as recently as October 6th, 2022. The research team needs to enroll 100 individuals from 1 participating hospital or medical facility."
Is this research still looking for participants?
"The clinical trial is currently looking for patients, as seen on clinicaltrials.gov. This specific trial was originally posted on May 18th, 2021 and was most recently edited on October 6th, 2022."
Can you provide more information on other investigations utilizing Fisetin?
"At this moment, there are 36 different ongoing trials investigating Fisetin. Out of these, 2 have reached Phase 3. The preponderance of these studies are situated in San Francisco; however, 538 other medical locations are also running similar research."
Why is Fisetin often given to patients?
"Fisetin has potential therapeutic benefits for diabetic nephropathy patients. Additionally, it is sometimes used to mitigate the symptoms of left ventricular hypertrophy, proteinuria, and hypertensive disease."
Are people over the age of 20 able to participate in this trial phase?
"This particular study is only open to people aged 40 to 85. In contrast, there are 43 clinical trials aimed at patients under 18 and 724 studies for individuals over the age of 65."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
How responsive is this trial?
Typically responds via
Most responsive sites:
- The Steadman Clinic: < 24 hours
Average response time
- < 1 Day
Share this study with friends
Copy Link
Messenger